Roubaix Capital LLC Increases Stock Holdings in Cellebrite DI Ltd. $CLBT

Roubaix Capital LLC lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 108.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 303,215 shares of the company’s stock after buying an additional 157,536 shares during the quarter. Cellebrite DI makes up about 1.9% of Roubaix Capital LLC’s holdings, making the stock its 29th largest position. Roubaix Capital LLC’s holdings in Cellebrite DI were worth $4,178,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cooper Creek Partners Management LLC acquired a new stake in Cellebrite DI in the 3rd quarter valued at about $55,999,000. Capital International Investors acquired a new position in Cellebrite DI in the fourth quarter valued at $41,073,000. Invesco Ltd. lifted its position in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after buying an additional 2,054,644 shares during the period. Artisan Partners Limited Partnership acquired a new stake in shares of Cellebrite DI during the fourth quarter valued at about $25,871,000. Finally, Pertento Partners LLP increased its holdings in Cellebrite DI by 28.2% during the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after purchasing an additional 1,311,109 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 158,191 shares of company stock worth $2,479,438. Company insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CLBT shares. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, DA Davidson assumed coverage on Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Trading Down 2.5%

NASDAQ CLBT opened at $15.44 on Friday. The company has a 50-day moving average price of $14.01 and a two-hundred day moving average price of $14.43. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 55.14, a price-to-earnings-growth ratio of 1.91 and a beta of 1.17.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.